MERCK KGAA

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1668-01-01

Employees: 62.9K

Market Cap: $84.2B

Website: http://www.merckgroup.com/de

Clinical Trials

Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

Completed

Conditions: Turner Syndrome
Growth Hormone Deficiency
Chronic Renal Failure
Small for Gestational Age

First Posted Date: 2008-08-20

Last Posted Date: 2014-03-11

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 834

Registration Number: NCT00738205

Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 1

Completed

Conditions: Squamous Cell Cancer

Interventions: Drug: Cilengitide 2000 mg once weekly
Drug: Cilengitide 2000 mg twice weekly
Drug: Cetuximab
Drug: 5-fluorouracil (5-FU)
Drug: Cisplatin

First Posted Date: 2008-06-25

Last Posted Date: 2014-04-30

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 184

Registration Number: NCT00705016

Locations: 🇨🇭
Research Site, Geneva, Switzerland

Long Term Follow up Study of Predictive Markers in GHD and TS Children

Completed

Conditions: Growth Hormon Deficiency
Turner Syndrome in Pre-pubertal Children

First Posted Date: 2008-06-18

Last Posted Date: 2014-02-19

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 182

Registration Number: NCT00699855

ChangE From Any Systemic psoriasiS therapY to Raptiva

Phase 4

Terminated

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)

First Posted Date: 2008-06-16

Last Posted Date: 2014-02-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 70

Registration Number: NCT00697593

Locations: 🇨🇦
Probity Medical Research, City Waterloo, Ontario, Canada

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Cetuximab
Drug: Capecitabine
Drug: Cisplatin

First Posted Date: 2008-05-15

Last Posted Date: 2014-07-21

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 904

Registration Number: NCT00678535

Locations: 🇬🇧
Research site, Manchester, United Kingdom
🇨🇳
Research Site, Taipei, Taiwan

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Rituximab
Drug: Atacicept
Drug: Placebo matched to atacicept

First Posted Date: 2008-04-23

Last Posted Date: 2016-12-30

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 27

Registration Number: NCT00664521

Locations: 🇬🇧
Research Site, Norwich, United Kingdom

Transition to Rebif New Formulation

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Rebif New Formulation + prophylactic Ibuprofen
Drug: Rebif New Formulation + ibuprofen PRN

First Posted Date: 2008-02-20

Last Posted Date: 2014-02-27

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 117

Registration Number: NCT00619307

Locations: 🇩🇪
Local Medical Information, Munich, Germany

AS900672-Enriched in Ovulation Induction

Phase 2

Terminated

Conditions: Ovulation Induction

Interventions: Drug: AS900672-Enriched 10 microgram (mcg)
Drug: AS900672-Enriched 20 mcg
Drug: AS900672-Enriched 30 mcg
Drug: AS900672-Enriched 40 mcg
Drug: Follitropin alfa 75 international unit (IU)
Drug: Recombinant human chorionic gonadotropin (r-hCG)

First Posted Date: 2007-11-04

Last Posted Date: 2014-02-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 71

Registration Number: NCT00553514

Locations: 🇨🇭
Merck Serono S.A., Geneva, Switzerland

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: AS900672-Enriched 50 microgram (mcg)
Drug: AS900672-Enriched 100 mcg
Drug: AS900672-Enriched 150 mcg
Drug: Follitropin alfa 150 international unit (IU)
Drug: Recombinant human chorionic gonadotropin (r-hCG)

First Posted Date: 2007-07-23

Last Posted Date: 2014-02-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 520

Registration Number: NCT00505752

Locations: 🇺🇸
Local US Medical Information Office, Rockland, Massachusetts, United States

r-hLIF for Improving Embryo Implantation in IVF

Phase 1

Completed

Conditions: Infertility Implantation Failure

First Posted Date: 2007-07-20

Last Posted Date: 2017-01-04

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 50

Registration Number: NCT00504530

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy